CPT code 0308U designates a Proprietary Laboratory Analyses (PLA) test — HART CADhs® from Prevencio Inc. — that measures three plasma proteins and applies an algorithm to produce a risk score for coronary artery stenosis or obstruction. As a PLA code, 0308U maps to a single manufacturer-specific assay and is used where results may affect diagnostic pathways and downstream care decisions for suspected coronary artery disease.

Key payers in the national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns and benchmarks where available, clarifies clinical context for ordering and interpretation, and summarizes relevant policy implications for laboratory and cardiology service lines.

Readers will learn the clinical purpose of the test, typical sites of service and operational considerations for labs and outpatient providers, and which major payers are included in the coverage review. Data limitations where input fields are incomplete are noted explicitly as "Data not available in the input." The goal is to provide a concise reference for billing, coding, and clinical teams evaluating use of CPT code 0308U in practice.